NCT00873041 - Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study | Biotech Hunter

Enrollment

166

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2012

Conditions

Non-transfusion Dependent Thalassemia

Interventions

DRUG

deferasirox

Supplied as 125 mg, 250 mg and 500 mg tablets.

DRUG

placebo

Supplied as matching 125 mg, 250 mg and 500 mg tablets.

Trial Locations (21)

New York Presbyterian Hospital/Weill Medical College of Cornell University, New York

Children's Hospital & Research Center Oakland, Oakland

Children's Memorial Hospital/Division of Hematology/Oncology, Chicago

Novartis Investigative Site, Athens

Novartis Investigative Site, Pátrai

Novartis Investigative Site, Thessaloniki

Novartis Investigative Site, Cagliari

Novartis Investigative Site, Genova

Novartis Investigative Site, Milan

Novartis Investigative Site, Napoli

Novartis Investigative Site, Rome

Novartis Investigative Site, Beirut

Novartis Investigative Site, Ampang Selangor

Novartis Investigative Site, Kuala Lumpur

Novartis Investigative Site, Taipei

Novartis Investigative Site, Bangkok

Novartis Investigative Site, Adana

Novartis Investigative Site, Ankara

Novartis Investigative Site, Istanbul

Novartis Investigative Site, Izmir

Novartis Investigative Site, London